Photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study

Retinal Diseases

Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial

Ophthalmology.

van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, Peters PJH, Dijkman G, Souied EH, MacLaren RE, Querques G, Downes SM, Hoyng CB, Boon CJF

doi: 10.1016/j.ophtha.

Macular DiseasesRetinal Diseases

One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration

Br J Ophthalmol.

Braimah IZ, Agarwal K, Mansour A, Chhablani J; Ziv-aflibercept Study Group

doi: 10.1136/bjophthalmol-

COMMENTED

Role of the Complement System in Chronic Central Serous Chorioretinopathy: A Genome-Wide Association Study

JAMA Ophthalmol.

Schellevis RL, van Dijk EHC, Breukink MB, Altay L, Bakker B, Koeleman BPC, Kiemeney LA, Swinkels DW, Keunen JEE, Fauser S, Hoyng CB, den Hollander AI, Boon CJF, de Jong EK

doi: 10.1001/jamaophthalmol.

Further Publications

Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial

Am J Ophthalmol

van Rijssen TJ, van Dijk EHC, Tsonaka R, Feenstra HMA, Dijkman G, Peters PJH, Diederen RMH, Hoyng CB, Schlingemann RO, Boon CJF

doi: 10.1016/j.ajo.2021.06.020

COMMENTED

Retinal Diseases

An international collaborative evaluation of central serous chorioretinopathy: different therapeutic approaches and review of literature. The European Vitreoretinal Society central serous chorioretinopathy study

★ 1 Recommended and commented by Dr habil. Gábor Márk Somfai, PhD, Faculty Member

doi: 10.1111/aos.14319.

Retinal Diseases

RESPONSE OF CHOROIDAL ABNORMALITIES TO PHOTODYNAMIC THERAPY VERSUS MICROPULSE LASER IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Place Trial Report No. 4

Retina

van Rijssen TJ, Hahn LC, van Dijk EHC, Tsonaka R, Scholz P, Breukink MB, Blanco-Garavito R, Souied EH, Keunen JEE, MacLaren RE, Querques G, Fauser S, Downes SM, Hoyng CB, Boon CJF

doi: 10.1097/IAE.0000000000003157

Retinal Diseases

Cross-over to photodynamic therapy or micropulse laser after failure of primary treatment of chronic central serous chorioretinopathy

Am J Ophthalmol.

van Rijssen TJ, van Dijk EHC, Scholz P, Breukink MB, Dijkman G, Peters PJH, Tsonaka R, MacLaren RE, Downes SM, Fauser S, Boon CJF, Hoyng CB

doi: 10.1016/j.ajo.2020.04.007.

Association of a Haplotype in the NR3C2 Gene, Encoding the Mineralocorticoid Receptor, With Chronic Central Serous Chorioretinopathy

JAMA Ophthalmol.

van Dijk EH, Schellevis RL, van Bergen MG, Breukink MB, Altay L, Scholz P, Fauser S, Meijer OC, Hoyng CB, den Hollander AI, Boon CJ, de Jong EK

doi: 10.1001/

Retinal Diseases

GENETIC RISK FACTORS IN ACUTE CENTRAL SEROUS CHORIORETINOPATHY

Retina.

Mohabati D, Schellevis RL, van Dijk EHC, Altay L, Fauser S, Hoyng CB, De Jong EK, Boon CJF, Yzer S

doi: 10.1097/IAE.

Related content

Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial

One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration

Role of the Complement System in Chronic Central Serous Chorioretinopathy: A Genome-Wide Association Study

Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial

An international collaborative evaluation of central serous chorioretinopathy: different therapeutic approaches and review of literature. The European Vitreoretinal Society central serous chorioretinopathy study

RESPONSE OF CHOROIDAL ABNORMALITIES TO PHOTODYNAMIC THERAPY VERSUS MICROPULSE LASER IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Place Trial Report No. 4

Cross-over to photodynamic therapy or micropulse laser after failure of primary treatment of chronic central serous chorioretinopathy

Association of a Haplotype in the NR3C2 Gene, Encoding the Mineralocorticoid Receptor, With Chronic Central Serous Chorioretinopathy

GENETIC RISK FACTORS IN ACUTE CENTRAL SEROUS CHORIORETINOPATHY